Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5681870 | 0.87 | CA12 (0.75) | LMNACYP1A2CYP2D6CYP2C19CNR1 | |
| SCHEMBL4268220 | 0.85 | LMNA (0.62) | LMNACYP1A2CYP2D6CYP2C19CNR1 | |
| SCHEMBL2191045 | 0.85 | KDM4E (0.65) | LMNACYP1A2CYP2D6CYP2C19GAA | |
| SCHEMBL9925290 | 0.83 | HPGD (0.62) | LMNACNR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3316967 | 0.83 | HPGD (0.68) | LMNACNR1TSHRCA12CA1 | |
| SCHEMBL2792326 | 0.83 | HPGD (0.54) | LMNACYP1A2CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL6850677 | 0.83 | ESRRG (0.53) | LMNACA12CA1CA2CA9 | |
| SCHEMBL20052590 | 0.83 | LMNA (0.47) | LMNACYP1A2CYP2D6CYP2C19CNR1 | |
| SCHEMBL4582082 | 0.82 | TAAR1 (0.65) | LMNACYP1A2CYP2D6CYP2C19CNR1 | |
| SCHEMBL696928 | 0.82 | HDAC3 (0.62) | L3MBTL1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100500665-C | Triazolo-pyrimido-thioacetamide compounds, preparation method and uses | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-06-17 | — | — | CN | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
| CN-1962662-A | Triazolo-pyrimido-thioacetamide compounds, preparation method and uses | UNIV ZHEJIANG TECHNOLOGY (CN) | 2007-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | HTR2B, HTR2A, HTR3B | LMNA 2783/4885CYP1A2 147/4885CYP2D6 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.